U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT03394937) titled 'Study to Assess Safety and Tolerability of Intranodal ECI-006 in Melanoma Patients With no Evidence of Disease' on Nov. 28, 2017.
Brief Summary: The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens.
ECI-006 will be administered 5 times by injection in a lymph node in the groin or armpit.
ECI-006 activates key immunologically active cells to direct the immune system against the cancer. Expected potential risks for ECI-006 are non-serious and related to the local administration of th...